GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-07-12| Trials & Approvals

Sanofi’s siRNA Therapy Reduces Bleeds in Hemophilia, Meets Primary Endpoint

by Joy Lin
Share To

Preventive treatment with fitusiran, a small interference RNA (siRNA) therapeutic, reduced bleeds by 61% in patients with hemophilia A or B, with or without inhibitor, who have previously received factor or bypassing agent (BPA) prophylaxis, said Sanofi. The results of the Phase 3 ATLAS-PPX study evaluating fitusiran met the primary endpoint. 

The data was presented at the International Society of Thrombosis and Haemostasis (ISTH) 2022 Congress. 

 

Reducing Bleeds by 61.1%

 

Key findings from the Phase 3 study showed that fitusiran prophylaxis resulted in an overall median annualized bleeding rate (ABR) of 0.0, compared to a median ABR of 4.4 with prior prophylaxis. This siRNA therapeutic significantly reduced estimated annual bleeding by 61.1% compared to factor or BPA prophylaxis. During the trial, 63.1% of patients treated with fitusiran experienced zero treated bleeds compared to. 16.9% with prior factor or BPA prophylaxis. 

The most common side effects of fitusiran treatment included increased alanine aminotransferase, nasopharyngitis, and upper respiratory tract infection. Thromboembolic events were reported in 2 patients (3.0%), which were consistent with previously identified risk of fitusiran.

Related article: Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries

 

Treating Hemophilia Comes With Challenges

 

Hemophilia is an inherited bleeding disorder caused by a deficiency in blood clotting factors, which leads to spontaneous and excessive bleeding. 

The disease is typically treated with replacement of the clotting factors, but the body’s immune system may generate inhibitors to the replacement therapy, creating complications. For people who have developed a high level of inhibitors, BPA prophylaxis is used to circumvent the need for the missing clotting factors and generate thrombin. In recent years, several therapeutic approaches show promise as complementary or alternative treatments for hemophilia. 

One of these approaches, siRNA, silences genes by binding to target mRNA, inducing its cleavage which results in degradation. Fitusiran targets the anti-clotting protein antithrombin. By lowering levels of antithrombin, the drug promotes thrombin generation to restore hemostasis (the body’s response to bleeding) and prevent bleeding. 

Fitusiran uses Alnylam’s ESC-GaINAc conjugate technology which enables subcutaneous dosing with increased potency and durability. It may have the potential to provide prophylactic treatment for people with hemophilia A or B, with or without inhibitors, with as few as six injections per year. 

However, the investigational drug has its share of challenges. Fitusiran ran into its first FDA clinical hold in 2017 after a patient died due to a blood clot during a Phase 2 study. The hold was resolved within the year, but a second hold followed in 2020 as Sanofi investigated new clotting complications resulting from fitusiran treatment. Sanofi has since switched to a lower dosing regimen for fitusiran, but has said regulatory filings may be delayed until 2024.

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Pre-JPM 2025: The Quiet Deals You May Have Missed Before the Big Show
2025-01-16
R&D
Teva and Sanofi’s Best-in-Class IBD Drug a Game-Changer in the Antibody Therapeutics Arena
2024-12-18
Novartis Invests $745M to Compete with BMS and Lilly in the Radiopharma Race
2024-11-19
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top